Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
Mesalamine
mesalamine
- Formulary Mesalamine Product Formulary
- Restricted sfRowasa --> Restricted to patients who have sulfite/sulfur allergy ~OR~ are intolerant to regular mesalamine enema due to sulfite content.
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Pentasa | CAPSULE, EXTENDED RELEASE, ORAL | 250 mg, 500 mg | ||||
| Apriso | CAPSULE, EXTENDED RELEASE, ORAL | 375 mg | ||||
| Delzicol | DELAYED RELEASE CAPSULE, ORAL | 400 mg | ||||
| Lialda | DELAYED RELEASE TABLET, ORAL | 1.2 g | ||||
| Asacol | DELAYED RELEASE TABLET, ORAL | 400 mg | ||||
| Asacol HD | DELAYED RELEASE TABLET, ORAL | 800 mg | ||||
| sfRowasa (sulfite free) | ENEMA, RECTAL | 4 g/60 mL | ||||
| Canasa | SUPPOSITORY, RECTAL | 1000 mg |
Last updated: Dec. 21, 2017
- Formulary, Not Routinely Stocked: sfRowasa
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
NOTES
mesalamine (Apriso)
mesalamine (Delzicol)
Apriso 1.5 g daily interchanged to Delzicol 400 mg QID
mesalamine (Asacol)
mesalamine (Dezicol)
mesalamine (Asacol HD)
mesalamine (Dezicol)
Apriso HD 800 mg TID interchanged to Delzicol (400 mg x 2) TID
Asacol 400 mg tablets have been discontinued. They have been replaced with Delzicol 400 mg capsules (bioequivalent).
Asacol HD is classified as non-formulary, not stocked. Interchange to Delzicol (formerly Asacol) at the same dosing regimen.
Rowasa Sulfite Free is classified as formulary, not generally stocked - to be used as a second line drug in patients with sulfite allergy or who cannot tolerate the regular mesalamine enema product.
Reviewed: April 24, 2007 (Lialda), and February 26, 2009 (Apriso), and November 17, 2009 (Asacol HD), and June 22, 2010 (Rowasa SF enema), and June 25, 2013 (Delzicol)